US EditionWAVE trial update reports sustained 12-month survival benefit - Interventional News
Summary by Interventional News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
WAVE trial update reports sustained 12-month survival benefit - Interventional News
Dheeraj Rajan Twelve-month results from the WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal trial show a statistically significant improvement in target lesion primary patency (TLPP) with the Wrapsody (Merit Medical) cell-impermeable endoprosthesis (CIE) when compared to percutaneous transluminal angioplasty (PTA). The prospective, multicentre, international WAVE trial, conducted across 43 centres in the USA, South America and the UK, incl…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
